Comment on the article by Vázquez and Márquez-Garcia. High-risk vs. low-risk for thrombo-embolic events: who are in the intermediate-risk group? What should be done then?
Although high risk and low risk profile for thrombo-embolic events have been extensively and intensively investigated in multi-centre trials and described in detail in atrial fibrillation guidelines, the management of those at otherwise intermediate risk is still a 'no-one's zone'. Individual risk profile is mandatory to identify those who will benefit of anti-coagulation therapy and large-scale clinical trials are still awaited to define efficacy and efficiency profile in intermediate-risk group.
Benchimol-Barbosa
Paulo Roberto
PR
Barbosa-Filho
José
J
D000368:Aged; D001281:Atrial Fibrillation / Q000150:complications*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D011379:Prognosis; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control
D005343:Fibrinolytic Agents